[Pharmacokinetics of breviscapine and its beta-cyclodextrin complex in rats].
OBJECTIVE
To establish RP-HPLC method for determination of plasma scutellarin concentration and study of the pharmacokinetic behavior of scutellarin in rat after ig administration of breviscapine and its beta-cyclodextrin complex (breviscapine-beta-CD).


METHODS
Mobile phase composed of methanol and acetate buffer. The column was Shim-pack C18. Twelve rats randomized into 2 groups were separately given breviscapine and breviscapine-beta-CD at single dose of 10.8 mg.kg(-1). Drug in plasma was extracted and determined by HPLC. The pharmacokinetic parameters were calculated by 3P97 software.


RESULTS
Linearity was obtained over the range of 10-400 ng.mL(-1). The recovery was 95.32%-98.81%. C(max) and AUC(0-12 h) of breviscapine were (154 +/- 18) ng.mL(-1) and (710 +/- 126) ng.h.mL(-1). For breviscapine-beta-CD, C(max) and AUC(0-12 h) were (328 +/- 31) ng.mL(-1) and (1,093 +/- 200) ng.h.mL(-1), respectively. There were significant differences of AUC(0-12 h) between breviscapine and breviscapine-beta-CD (P < 0.01).


CONCLUSIONS
The assay method was suitable for the determination of scutellarin plasma concentration in rat. Brevescapine-beta-CD showed greater absorption compared with that of brevescapine.
Zhang
Hai-Yan
HY
Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210038, China.
Ping
Qi-Neng
QN
Guo
Jian-Xin
JX
Cao
Feng
F
D000818:Animals; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004339:Drug Compounding; D049919:Erigeron / Q000737:chemistry; D005419:Flavonoids / Q000097:blood / Q000302:isolation & purification / Q000493:pharmacokinetics*; D008297:Male; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D047392:beta-Cyclodextrins / Q000097:blood / Q000493:pharmacokinetics*
D005419:Flavonoids; D047392:beta-Cyclodextrins; C061097:breviscapine